BiomeDx presents multi-centric validation of BiomeOne® at the ESMO Congress 2022
VIENNA, September 19th:
The ESMO congress 2022 was held in Paris, between the 9-14 September 2022 (https://www.esmo.org/meetings/past-meetings/esmo-congress-2022). BiomeDx presented their latest results from the validation study of BiomeOne®, a stool-based microbiome test to predict the response to cancer immunotherapy (immune checkpoint inhibitors). This is the first stool-based test of its kind to be launched into the market, and will certainly pave the way to the development of non-invasive tests based on the intestinal microbiome.
BiomeOne has been CE-IVD marked in May 2022, and is now available for purchase in our website. The test has been released for ICI response prediction in non-small-cell lung cancer, renal cell carcinoma and malignant melanoma patients. Ongoing research aims to further expand the applicability to other tumour types. Read more on BiomeOne.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.